MA71567A - Procédé de traitement de maladies ou de troubles d'organes avec des inhibiteurs d'ask1 - Google Patents
Procédé de traitement de maladies ou de troubles d'organes avec des inhibiteurs d'ask1Info
- Publication number
- MA71567A MA71567A MA71567A MA71567A MA71567A MA 71567 A MA71567 A MA 71567A MA 71567 A MA71567 A MA 71567A MA 71567 A MA71567 A MA 71567A MA 71567 A MA71567 A MA 71567A
- Authority
- MA
- Morocco
- Prior art keywords
- disorders
- organ diseases
- treating organ
- ask1 inhibitors
- ask1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263368961P | 2022-07-20 | 2022-07-20 | |
| EP23843862.6A EP4558146A1 (fr) | 2022-07-20 | 2023-07-19 | Procédé de traitement de maladies ou de troubles d'organes avec des inhibiteurs d'ask1 |
| PCT/US2023/070517 WO2024020458A1 (fr) | 2022-07-20 | 2023-07-19 | Procédé de traitement de maladies ou de troubles d'organes avec des inhibiteurs d'ask1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71567A true MA71567A (fr) | 2025-05-30 |
Family
ID=89618637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71567A MA71567A (fr) | 2022-07-20 | 2023-07-19 | Procédé de traitement de maladies ou de troubles d'organes avec des inhibiteurs d'ask1 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20260021084A1 (fr) |
| EP (1) | EP4558146A1 (fr) |
| JP (1) | JP2025525586A (fr) |
| KR (1) | KR20250044687A (fr) |
| CN (1) | CN119894519A (fr) |
| AR (1) | AR129959A1 (fr) |
| AU (1) | AU2023311333A1 (fr) |
| IL (1) | IL318468A (fr) |
| MA (1) | MA71567A (fr) |
| MX (1) | MX2025000759A (fr) |
| TW (1) | TW202412761A (fr) |
| WO (1) | WO2024020458A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202547513A (zh) * | 2024-05-06 | 2025-12-16 | 法商Genfit公司 | 敗血症的治療 |
| WO2026057806A1 (fr) * | 2024-09-13 | 2026-03-19 | Genfit | Forme posologique injectable de 2-[6-(4-cyclopropyl-4h-1,2,4-triazol-3-yl)-2-pyridyl]-5-morpholinocarbonyl-1-isoindolinone |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190221A1 (ar) * | 2017-04-05 | 2019-09-23 | Seal Rock Therapeutics Inc | مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها |
| WO2020006429A1 (fr) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Inhibiteurs d'isoindolin-1-one ask1 et leurs procédés d'utilisation |
| AR116024A1 (es) * | 2018-08-29 | 2021-03-25 | Seal Rock Therapeutics Inc | Métodos de tratamiento de enfermedades neurodegenerativas |
-
2023
- 2023-07-19 WO PCT/US2023/070517 patent/WO2024020458A1/fr not_active Ceased
- 2023-07-19 TW TW112126949A patent/TW202412761A/zh unknown
- 2023-07-19 AR ARP230101885A patent/AR129959A1/es unknown
- 2023-07-19 KR KR1020257004959A patent/KR20250044687A/ko active Pending
- 2023-07-19 CN CN202380066474.3A patent/CN119894519A/zh active Pending
- 2023-07-19 EP EP23843862.6A patent/EP4558146A1/fr active Pending
- 2023-07-19 JP JP2025502857A patent/JP2025525586A/ja active Pending
- 2023-07-19 AU AU2023311333A patent/AU2023311333A1/en active Pending
- 2023-07-19 US US18/996,525 patent/US20260021084A1/en active Pending
- 2023-07-19 MA MA71567A patent/MA71567A/fr unknown
- 2023-07-19 IL IL318468A patent/IL318468A/en unknown
-
2025
- 2025-01-17 MX MX2025000759A patent/MX2025000759A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025000759A (es) | 2025-05-02 |
| TW202412761A (zh) | 2024-04-01 |
| AU2023311333A1 (en) | 2025-02-27 |
| WO2024020458A1 (fr) | 2024-01-25 |
| AR129959A1 (es) | 2024-10-16 |
| KR20250044687A (ko) | 2025-04-01 |
| US20260021084A1 (en) | 2026-01-22 |
| IL318468A (en) | 2025-03-01 |
| JP2025525586A (ja) | 2025-08-05 |
| CN119894519A (zh) | 2025-04-25 |
| EP4558146A1 (fr) | 2025-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA71567A (fr) | Procédé de traitement de maladies ou de troubles d'organes avec des inhibiteurs d'ask1 | |
| EP4440460A4 (fr) | Système et procédé de diagnostic et de traitement de troubles du rythme biologique | |
| EP3955954A4 (fr) | Polythérapie pour la modulation de l'homéostasie de l'acide biliaire et le traitement des troubles et de maladies de l'acide biliaire | |
| EP4395753A4 (fr) | Fenfluramine pour le traitement de maladies et d'affections démyélinisantes | |
| EP4355878A4 (fr) | Traitement de maladies et de troubles liés à mtres1 | |
| EP4125865A4 (fr) | Compositions et méthodes de traitement de maladies liées à l'âge et de troubles du vieillissement prématuré | |
| EP3932404A4 (fr) | Méthode de traitement d'une stéatose hépatique et/ou d'une stéatohépatite | |
| EP4122488A4 (fr) | Procédé et médicament pour le traitement de la maladie d'alzheimer | |
| EP3681477A4 (fr) | Méthode et composition améliorée pour le traitement d'états pathologiques, de maladies ou de troubles sensibles aux triterpènes | |
| EP4106815A4 (fr) | Méthode pour le traitement de l'asthme ou d'une maladie allergique | |
| EP4444718A4 (fr) | Méthodes de traitement du tspt et de troubles neurologiques | |
| EP3405201A4 (fr) | Carbonate de calcium amorphe stabilisé pour le traitement de maladies ou d'affections neurologiques ou musculaires et l'infertilité | |
| EP4349326A4 (fr) | Composition de gouttes oculaires pour la prévention ou le traitement de maladies ophtalmiques et son procédé de préparation | |
| EP4146201A4 (fr) | Traitement de maladies prolifératives du snc | |
| EP4444694A4 (fr) | Composés et leur procédé d'utilisation pour traiter des maladies bactériennes | |
| EP4263087C0 (fr) | Procédé de traitement de fer fondu | |
| EP4099997A4 (fr) | Méthodes et compositions pour le traitement de maladies | |
| EP4259173A4 (fr) | Composés pour le traitement de maladies et de troubles oculaires | |
| EP4284392A4 (fr) | Traitement de l'astigmatisme | |
| EP4514357A4 (fr) | Méthodes de traitement de troubles neurologiques | |
| IL321373A (en) | Treatment of mst1-related diseases and disorders | |
| EP4100006A4 (fr) | Dérivés d'imidazole fusionnés substitués et procédés de traitement de troubles oculaires réfractifs | |
| EP4188407A4 (fr) | Méthode de traitement de maladies neurodégénératives par administration de benfotiamine ou d'un de ses dérivés | |
| EP4125968A4 (fr) | Traitement de troubles respiratoires | |
| EP4143202A4 (fr) | Méthode de traitement de maladies à médiation par ship1 à l'aide de dérivés de pelorol |